Virtual Library
Start Your Search
C. Ballesteros-Merino
Author of
-
+
P1.07 - Immunology and Immunotherapy (ID 693)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Immunology and Immunotherapy
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.07-019 - Immune Cell Infiltrates in Non-Small Cell Lung Cancer and Interleukin-22 Expression (ID 9238)
09:30 - 09:30 | Author(s): C. Ballesteros-Merino
- Abstract
Background:
In non-small cell lung cancer (NSCLC) the TNM staging remains standard for prognostic assessment and therapy decisions. Nevertheless, stage-specific outcomes vary significantly, indicating a need for additional prognosticators.Lymphocytic infiltrates are found in 6-11% of NSCLC patients and associated with a significant increase in disease-free and overall survival (OS). We now want to assess T cells and PD-L1[+] cells in tissue microarrays (TMAs) cored at the invasive margin (IM) and tumor center (CT) via multispectral imaging. We asked the question of their link to interleukin-22 (IL-22). Furthermore, we want to elucidate the role of IL-22 in prognosis, therapy response and recurrence.
Method:
TMAs were generated from formalin-fixed paraffin embedded tissue of 89 curatively resected patients with stage IA-IIIA NSCLC. TMAs included each 3 cores from CT and IM, selected from areas with the most dense lymphocytic infiltrates. Immunolabelling followed mIHC technique for PD-L1, CD8, CD3, FoxP3, CD163 and Cytokeratin. IL-22 expression was analyzed by immunohistochemistry (double-staining: IL-22, CD3).
Result:
We could show that the ratio of CD8[+] cells in CT compared to IM is significantly higher in stage I than stage II/III NSCLC. A similar pattern was seen for CD3[+], but not for ratios of PD-L1[+], FoxP3[+] or CD163[+]. Based on the CT/IM ratios of CD8[+] and PD-L1[+] we established an 'Invasive Score' ranging from 0–2. A Score of 0 (low CD8, low PD-L1) had a median OS of 45 months. A score of 1 (high CD8 or PD-L1) had a median OS of 53 months. A score of 2 (high CD8 and PD-L1) had a 62% survival rate at 72-months: Combining the rate of CD8 T cell infiltrates with PD-L1 positivity in the tumor is a stronger predictor for survival than one based only on CD8 CT/IM ratio. We will now combine these results with the IL-22 expression and present the respective progression free and OS data.
Conclusion:
Multispectral assessment of CD8 and PD-L1 performed on “hot-spots” NSCLC does show a clear correlation with clinical outcome: A tumor-controlling immune response appears to be associated with the permeability of the tumor to CD8 cells. This is consistent with other reports that immune infiltrates are associated with improved outcome. Current studies are seeking to verify these findings in a larger cohort of patients with NSCLC. *Authors Stump and Reu contributed equally to this study. Supported by the Harder Family, Lynn and Jack Loacker, Robert W. Franz, Wes and Nancy Lematta, the Murdock Trust and Providence Medical Foundation.
